0001326110-23-000106.txt : 20230828 0001326110-23-000106.hdr.sgml : 20230828 20230828205831 ACCESSION NUMBER: 0001326110-23-000106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230825 FILED AS OF DATE: 20230828 DATE AS OF CHANGE: 20230828 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sachs David C. CENTRAL INDEX KEY: 0001848899 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37507 FILM NUMBER: 231217725 MAIL ADDRESS: STREET 1: C/O IMMUNITYBIO, INC. STREET 2: 3530 JOHN HOPKINS COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunityBio, Inc. CENTRAL INDEX KEY: 0001326110 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 431979754 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3530 JOHN HOPKINS COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (844) 696-5235 MAIL ADDRESS: STREET 1: 3530 JOHN HOPKINS COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: NantKwest, Inc. DATE OF NAME CHANGE: 20150713 FORMER COMPANY: FORMER CONFORMED NAME: Conkwest, Inc. DATE OF NAME CHANGE: 20140416 FORMER COMPANY: FORMER CONFORMED NAME: ZelleRx Corp DATE OF NAME CHANGE: 20050504 4 1 wk-form4_1693270702.xml FORM 4 X0508 4 2023-08-25 0 0001326110 ImmunityBio, Inc. IBRX 0001848899 Sachs David C. C/O IMMUNITYBIO, INC. 3530 JOHN HOPKINS COURT SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer 0 Restricted Stock Units 2023-08-25 4 A 0 141489 0 A Common Stock 141489 141489 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the RSUs subject to the award shall vest on September 1, 2023 and 70,745 of the RSUs subject to the award shall vest on January 31, 2024. /s/ Jason Liljestrom, as Attorney-in-Fact 2023-08-28